Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.9 ILa | +11.92% | +1.20% | -55.76% |
Sales 2024 * | 14.36M 5.33B | Sales 2025 * | 27.77M 10.31B | Capitalization | 54.6M 20.28B |
---|---|---|---|---|---|
Net income 2024 * | -47M -17.45B | Net income 2025 * | -36M -13.37B | EV / Sales 2024 * | 3.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.97 x |
P/E ratio 2024 * |
-2.28
x | P/E ratio 2025 * |
-
| Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRx Ltd.
1 day | +11.92% | ||
1 week | +1.20% | ||
Current month | -3.98% | ||
1 month | -21.40% | ||
3 months | -38.77% | ||
6 months | -60.05% | ||
Current year | -55.76% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
Aharon Schwartz
CHM | Chairman | 80 | 03-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-05 | 16.9 | +11.92% | 3,624,727 |
24-05-02 | 15.1 | -15.64% | 8,203,239 |
24-05-01 | 17.9 | +1.70% | 1,270,258 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 05, 2024 at 08:49 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.76% | 48.78M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- BLRX Stock